The first international standard for antibodies to double stranded DNA*

T E W FELTKAMP,¹ T B L KIRKWOOD,² R N MAINI,³ AND L A AARDEN¹

From the ¹Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands; the ²National Institute for Medical Research, Mill Hill, London; and the ³Kennedy Institute of Rheumatology, Hammersmith, London

SUMMARY This paper announces the availability of the first international standard for anti-double-stranded DNA (anti-dsDNA). The material, coded Wo/80, was obtained after recalcification of plasma taken from a patient with systemic lupus erythematosus. Vials were filled with 500 µl serum and freeze dried. The serum contains no other autoantibodies in measurable quantities. The vials should be stored at -20°C. The standard should be used for establishing national, regional, or local standards. In eight laboratories satisfactory results with the immunofluorescence technique on *Crithidia luciliae* were obtained; the titres varied between 1/20 and 1/640 (mean 1/160). In seven laboratories the Farr assay, with the so called 'Amersham kit', was performed. At a dilution of 1:40 a mean binding percentage of about 50% was observed. After reconstitution with 500 µl of distilled water, the vial contains 100 IU/500 µl or 200 IU/ml. The standard can be obtained from the custodian of WHO: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, PO Box 9190 1006 AD Amsterdam, The Netherlands.

Key words: anti-DNA, standardisation, WHO, Farr assay, *Crithidia luciliae*, IUIS.

Thirty years ago antibodies to DNA were first reported in sera from patients with systemic lupus erythematosus.¹⁻⁴ Numerous methods have been developed for the detection of these antibodies,⁵⁻⁸ and it has been generally agreed that for measurement of the amount of anti-DNA, serum dilutions should be tested. The results could then be expressed, depending on the method, either in arbitrary units per millilitre or as a titre.^{8,9}

During the first Bertine Koperberg Conference the need for an international standard anti-dsDNA antiserum was expressed.¹⁰ Such a standard serum should allow the development of national standards, which finally should lead to the use of local laboratory reference sera, enabling the expression of quantitative results in international units (IU).

The standardisation committee of the International

Union of Immunological Societies nominated for this purpose a subcommittee on anti-dsDNA. The chairman of this committee, T E W Feltkamp, received support from many workers all over the world (see 'Acknowledgments'). The nucleus of the committee, i.e., the authors of the present paper and E J Holborow and G D Johnson, agreed that the committee's task was to develop a reference standard serum which was available in a large quantity and contained anti-dsDNA activity, was stable when stored in freeze dried ampoules, and was suitable for use in at least the Farr assay and the immunofluorescence technique. These two techniques had performed consistently well in a comparative study organised by the Arthritis and Rheumatism Council of Great Britain⁶ and relied upon the use of dsDNA which was relatively free from contamination by single stranded DNA and nucleoprotein.⁷

Materials and methods

PATIENT WO

Patient Wo was a man, born in 1924, who developed

Accepted for publication 3 February 1988.

Correspondence to Professor T E W Feltkamp, c/o Publication Secretariat, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, PO Box 9406, 1006 AK Amsterdam, The Netherlands.

*This article is written on behalf of the International Union of Immunological Societies standardisation committee on anti-dsDNA.

pleuritis in 1954. Since 1954 he had also had arthralgia, arthritis, Raynaud's phenomenon, and skin rashes. In 1976 an exacerbation of his disease comprised serious skin involvement (exfoliative dermatitis, mouth ulcerations), thrombocytopenia ($50 \times 10^9/l$), and leucopenia ($1.3 \times 10^9/l$). Treatment was started with large doses of prednisone (80 mg daily). Anti-DNA was not found in the serum until July 1978. Since then the level of anti-DNA increased until an exacerbation in January 1979, during which the level dropped considerably in a few weeks. He then developed proteinuria with hyaline cylinders. In 1980 treatment with plasmapheresis was tried, but was unsuccessful. The patient developed serious mental depression and committed suicide.

PREPARATION OF STANDARD SERUM

The anti-dsDNA standard serum was prepared by recalcification of plasma (2 litres) of patient Wo with CaCl_2 to a final concentration of 15 mmol/l. Clotting was allowed to take place for four hours at 37°C , then for 16 hours at room temperature, after which the clot was removed by centrifugation. Neither hepatitis B surface antigens nor antihuman immunodeficiency virus were detected. The serum was divided among 1800 vials and freeze dried. The vials were back filled with dry, sterile, oxygen free nitrogen and stoppered in situ in the freeze drier. Labelling and oversealing of the vials was carried out by machine. Vial to vial analysis on 12 randomly

selected vials gave a between assay coefficient of variation of 0.8%. Vials of a patient with systemic lypus erythematosus, patient 'B', and a normal control, 'A', were also freeze dried. These were used for the collaborative study.

OTHER AUTOANTIBODIES

The serum Wo/80 was tested for several autoantibodies. Rheumatoid factors (latex test and Waaler-Rose test) and antiperinuclear factors could not be detected. Antibodies to extractable nuclear antigens were not detectable by the counterimmunoelectrophoresis method. Apart from antinuclear antibodies, no antibodies were demonstrated by the indirect immunofluorescence technique against thyroid, gastric parietal cells, mitochondria, liver cells, skin, cornea, islets of Langerhans, tubular membranes, salivary duct cells, cardiac muscle, smooth muscle, skeletal muscle, adrenocortex, and gluten. A radioimmunoprecipitation method demonstrated no antibodies to acetylcholine receptors.

Results

STABILITY TESTING

Thirty vials of Wo/80 were stored at -70°C until the onset of a fixed period during which the vials were stored at a specified temperature. All periods ended on the same date, on which all vials were opened and reconstituted. The contents were tested by the Farr assay (Table 1) and the immunofluorescence technique (Table 2).

Table 1 Accelerated degradation tests on freeze dried vials of Wo/80*

Temperature (°C)	Storage time				
	2 Weeks	1 Month	3 Months	6 Months	1 Year
-70					178
-20				185	172
4			172	167	180
Room temperature		178	185	156	156
37	180	183	149	136	125

*The results are expressed in local units of anti-DNA/ml (Farr assay) as described by Aarden and Smcenk.⁷

Table 2 Accelerated degradation tests on freeze dried vials of Wo/80 using the indirect immunofluorescence technique on *Crithidia luciliae*

Temperature (°C)	Storage time				
	2 Weeks	1 Month	3 Months	6 Months	1 Year
-70					1/80
-20				1/40	1/80
4			1/40	1/40	1/80
Room temperature		1/80	1/40	1/80	1/40
37	1/80	1/80	1/40	1/40	1/80

The relative potency estimates were used to fit an Arrhenius equation relating degradation rate to absolute temperature by the maximum likelihood method.¹¹ Data from the immunofluorescence technique assay (Table 2) were too variable for any conclusion to be drawn as there was no clear evidence of measurable degradation relative to the background error of the assay results. The data from the Farr assay (Table 1), however, provided a good fit to the Arrhenius model ($\chi^2=4.92$; $df=12$; $p>0.5$). When the Farr assay data were analysed it was assumed that the geometric coefficient of variation of individual potency ratios was around 8.8% (equivalent to a statistical weight of 750) because this was typical of the values obtained in the collaborative study; the exact figure for precision was not known as this had not been determined.

When the fitted Arrhenius equation was used to predict long term stability of Wo/80 at -20°C the estimated degradation rate was 0.045% a month or 0.54% a year.¹² The half life ($t_{1/2}$) at -20°C is 128 years. An approximate upper 95% confidence limit for this rate is 3.5% per year.¹³ These figures indicate an acceptable level of long term stability for Wo/80 when stored at -20°C or below. For periods of shipment the data indicate a predicted loss of 3.3% activity a month at 37°C and 1.1% activity a month at 20°C . These losses also appear to be acceptable.

Tests on the stability of the reconstituted content of Wo/80 when stored at -20°C also showed reasonable stability under these conditions (Table 3).

COLLABORATIVE STUDY

From the members of the subcommittee on standardisation of anti-dsDNA eight (see 'Acknowledgments') were selected for their experience in anti-dsDNA testing and willingness to cooperate in a study to see whether the serum Wo/80 could serve as a standard. The laboratories of these members

were situated in Amsterdam, Bethesda, Giessen, Le Jolla, London (two), Stockholm, and Toulouse.

From another centre outside these laboratories vials with 10 freeze dried serum samples Wo/80, A and B were shipped together with slides with *Crithidia luciliae* prepared by the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, (CLB), Amsterdam, ampoules of the WHO standard of fluorescein isothiocyanate (FITC) conjugated anti-immunoglobulin (480010), and kits for the Farr assay as produced and provided by Amersham International plc.¹⁴

The eight laboratories were asked to test the ampoules A, B, and Wo/80 on four separate dates with the immunofluorescence technique and the Farr assay according to fixed protocols. The tests had to be performed within six weeks.

The fixed protocols were as follows: Reconstitute the freeze dried standard Wo/80 and the serum samples A and B with 500 μl distilled water by gently adding the water to the inside of the glass vial. Replace the stoppers and leave the vials at room temperature for 10 minutes. Invert the vials to remove any remaining particles from the cap and leave for a further five minutes. Mix gently to obtain a homogeneous solution. The solution was equivalent to neat serum. Unless otherwise specified, all further dilutions were made with phosphate buffered saline (PBS; 0.01 M $\text{Na}_2\text{HPO}_4\text{-NaH}_2\text{PO}_4$, 0.1 M NaCl; pH 7.4).

FARR ASSAY AS PRESENTED IN THE 'AMERSHAM KIT'

Prepare 1:10 dilutions of Wo/80, serum A, and serum B by mixing 50 μl of the sample with 450 μl of borate buffered saline (buffer A in the kit). Make three further doubling dilutions of the samples using serum buffer (buffer B in the kit). Pipette 50 μl aliquots of all the dilutions into duplicate tubes, cover, and incubate at 56°C for 30 minutes. Allow the tubes to cool and add 50 μl of the ^{125}I labelled DNA provided to all tubes and mix gently. Incubate at 37°C for 60 minutes and then for a minimum of 18 hours at 4°C . Add to each tube 100 μl of the cold saturated ammonium sulphate solution provided, and mix immediately. Centrifuge the tubes at 1500 g for 15 minutes. Aspirate the supernatant and count the precipitate with a gammacounter. Draw dilution curves for all the samples.

IMMUNOFLUORESCENCE TECHNIQUE ON CRITHIDIA LUCILIAE

Prepare 1:10 dilutions of Wo/80, serum A, and serum B and make seven further doubling dilutions in PBS. Pipette 30 μl aliquots of all serum dilutions onto the spots of *C. luciliae* and incubate for 30

Table 3 Stability of the reconstituted content of vials Wo/80 if stored at -20°C *

Vial	Storage time after reconstitution (weeks)						
	0	8	10	11	21	23	24
A	296			270			233
B	250		222			238	
C	294	250			250		
D	250			256			

*Four vials were reconstituted. The contents were stored at -20°C and tested at given times. The results are expressed in local units of anti-DNA/ml (Farr assay).⁷

minutes at room temperature in a damp atmosphere. Rinse each slide quickly under the tap and wash in an excess of PBS for 30 minutes at room temperature, changing the PBS every 10 minutes. Add to each slide an excess of a 1:40 dilution in PBS of the WHO standard FITC conjugated sheep antihuman immunoglobulin preparation. Prevent any drying out of the slides during this procedure. Incubate for 30 minutes at room temperature in a humid atmosphere. Wash as previously. Mount the slides in 65% (w/v) sucrose in PBS pH 8.0. When a KP 560 barrier filter (Leitz) is available reading is made much easier by introduction of 0.5 µg/ml propidium iodide to the 65% (w/v) sucrose used for mounting. This stains the kinetoplast and nucleus red and facilitates localisation of the kinetoplast.

Read the slides with the local immunofluorescence microscope (magnification 500×). Reading can be done with a 50/1.00 water immersion objective. Tables 4 and 5 give the raw data. The eight laboratories are coded by numbers 1 to 8. The laboratories cooperated satisfactorily. Only laboratory 8 failed to perform the Farr assay. Laboratory 2 missed some results because of broken tubes. Laboratory 6 did not perform the Farr assay on four days but in duplicate on three days. The results of the first day testing of the Farr assay in laboratory 6 allowed no proper comparison with those of the other laboratories. The immunofluorescence technique gave no problems except for laboratory 6, who obtained negative results with serum B on the third day.

Table 4 Farr assay performed by eight laboratories using the 'Amersham kit' on three sera*

Laboratory	Test No	Wol80, dilution				A, dilution				B, dilution			
		1/10	1/20	1/40	1/80	1/10	1/20	1/40	1/80	1/10	1/20	1/40	1/80
1	1	85	72	55	36	13	13	13	13	61	41	28	20
	2	87	74	51	37	14	15	15	16	68	40	29	22
	3	82	70	51	35	13	14	14	15	69	46	32	23
	4	81	66	48	34	15	15	15	14	60	41	30	24
2	1	80	62	47	34	10	11	9	9	55	38	24	16
	2	77	49	46	31	18	14	14	14	41	29	29	24
	3	98	51	43	32	14	—	—	—	49	31	17	17
	4	62	46	36	22	11	11	10	9	38	24	21	11
3	1	85	69	51	38	18	16	17	16	52	37	24	20
	2	89	76	54	37	17	14	13	12	55	37	26	19
	3	88	77	53	35	18	15	12	12	54	36	25	20
	4	84	70	49	32	15	13	13	14	56	38	24	19
4	1	79	65	54	37	16	16	18	16	58	41	33	23
	2	85	71	58	22	16	17	16	15	66	47	56	26
	3	77	65	59	42	18	21	17	16	58	46	33	25
	4	95	82	61	46	17	18	18	18	67	50	37	28
5	1	83	72	54	40	17	15	16	16	61	44	35	26
	2	82	64	49	34	16	13	15	11	—	41	32	22
	3	64	56	44	33	13	14	14	14	52	38	26	19
	4	80	63	46	30	13	13	13	16	54	35	29	19
6	1	12	13	11	10	14	13	10	10	54	34	29	18
	2	86	71	54	38	16	15	16	15	63	44	31	26
	3	81	69	54	41	14	15	12	14	59	41	27	19
	4	—	—	—	—	—	—	—	—	—	—	—	—
7	1	83	66	46	30	8	8	9	10	60	36	22	16
	2	88	71	53	35	11	10	10	11	61	40	25	17
	3	87	71	50	33	11	10	10	11	56	37	23	16
	4	82	69	51	33	10	10	10	11	58	38	24	18
8	1	—	—	—	—	—	—	—	—	—	—	—	—
	2	—	—	—	—	—	—	—	—	—	—	—	—
	3	—	—	—	—	—	—	—	—	—	—	—	—
	4	—	—	—	—	—	—	—	—	—	—	—	—

*The results are expressed as a binding percentage.
—=not done.

Table 5 Immunofluorescence technique on *Critidia luciliae* performed by eight laboratories on three sera*

Laboratory	Test No	A, dilution								B, dilution							
		1/10	1/20	1/40	1/80	1/160	1/320	1/640	1/1280	1/10	1/20	1/40	1/80	1/160	1/320	1/640	1/1280
1	1	++	++	++	+	+	±	-	-	+	+	(+)	±	-	-	-	-
	2	+	+	+	±	(+)	(+)	-	-	+	+	±	-	-	-	-	-
	3	+	+	+	±	-	-	-	-	+	+	(+)	+	-	-	-	-
	4	+	+	+	+	(+)	(+)	-	-	+	+	+	+	-	-	-	-
2	1	+	+	(+)	-	-	-	-	-	+	(+)	-	-	-	-	-	-
	2	++	++	(+)	-	-	-	-	-	+	(+)	-	-	-	-	-	-
	3	+	+	(+)	±	-	-	-	-	+	(+)	±	±	-	-	-	-
	4	++	+	(+)	±	-	-	-	-	+	(+)	±	±	-	-	-	-
3	1	+++	+++	+++	+	-	-	-	-	++	+	(+)	-	-	-	-	-
	2	+++	+++	+++	+	(+)	-	-	-	++	+	+	-	-	-	-	-
	3	+++	+++	+++	+	(+)	-	-	-	++	+	+	+	-	-	-	-
	4	+++	+++	+++	+	(+)	-	-	-	++	+	+	+	-	-	-	-
4	1	+++	++	+	+	-	-	-	-	++	+	-	-	-	-	-	-
	2	+++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	3	+++	++	++	+	+	-	-	-	++	+	+	+	-	-	-	-
	4	+++	++	+	+	(+)	-	-	-	++	+	(+)	-	-	-	-	-
5	1	+++	+++	+++	+	-	-	-	-	++	+	+	-	-	-	-	-
	2	+++	+++	+++	+	+	(+)	-	-	+++	+	+	(+)	-	-	-	-
	3	+++	+++	+++	+	+	+	-	-	+++	+	+	+	-	-	-	-
	4	+++	+++	+++	+	+	+	-	-	+++	+	+	+	-	-	-	-
6	1	+++	++	++	+	±	-	-	-	++	+	(+)	-	-	-	-	-
	2	+++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	3	+++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	4	+++	++	++	+	+	-	-	-	+++	+	+	+	-	-	-	-
7	1	++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	2	++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	3	++	++	++	+	-	-	-	-	++	+	+	-	-	-	-	-
	4	++	+	+	+	-	-	-	-	+	+	+	-	-	-	-	-
8	1	+++	+++	+++	++	+	+	-	-	+++	+	+	+	-	-	-	-
	2	+++	+++	+++	++	+	(+)	-	-	+++	+	+	(+)	±	-	-	-
	3	+++	+++	+++	++	+	(+)	-	-	+++	+	+	+	-	-	-	-

*The results express degree of kinetoplast fluorescence.

FARR ASSAY

The dilution curves from each of the assays were plotted and examined visually for linearity and parallelism. As no replication was carried out in the individual assays the linearity and parallelism of the dilution curves could not be tested statistically. Within assays coefficients of variation were therefore not determined. It was clear from the graphs that preparation A had no detectable activity in this assay method, and the results for this material were not considered further. For preparation B several data points fell outside the linear part of the dilution curve, and these points also were excluded. In a small proportion of assays no valid comparison seemed possible, and these assays were therefore discarded. The remaining data were included in a parallel line assay analysis according to Finney,¹⁵ in which straight parallel lines were fitted for each assay, and, from these, potency ratios of the preparations versus Wo/80 were calculated.

Fig. 1 shows the distribution of the potency ratios of B versus Wo/80 from the individual assays; these ranged from 0.241 to 0.458. (A potency ratio R means that preparation B was estimated to be R times as potent as Wo/80.) Table 6 summarises these results and shows the geometric means and coefficients of variation within each laboratory. The laboratory means ranged from 0.260 to 0.365. One way analysis of variance among these means showed that the variation between laboratories was statistically significant ($F_{6,19}=4.30$, $p<0.01$) when compared with the variation within laboratories. The overall geometric mean potency ratio was 0.313 with a 95% confidence interval of 0.282–0.348.

IMMUNOFLUORESCENCE TECHNIQUE

The results were calculated as the ratios of the titres of B versus Wo/80 at which the first position response (+) was recorded. Fig. 1 (lower panel)

shows the distribution of potency ratios of B versus Wo/80, which ranged from 0.125 to 0.5. Most of the potency ratios were either 0.25 or 0.5, the bimodality of the distribution reflecting the fact that the potencies were calculated as the ratios of titres. Table 6 summarises the results, showing the geometric means and coefficients of variation within each laboratory. The laboratory means ranged from 0.25 to 0.5. One way analysis of variance among these means showed that, as with the Farr assay, the interlaboratory variation was statistically significant ($F_{7,23}=2.83$, $p<0.05$). The overall geometric mean potency ratio was 0.355 with a 95% confidence interval of 0.282–0.447.

For preparation B it appeared that the potency ratios by the two methods of assay were broadly similar. In Fig. 1 it can be seen that all the potency

Fig. 1 Distribution of potency ratios of serum B versus Wo/80, resulting from tests performed in eight laboratories (numbered 1–8) on four distinct days.

Table 6 Geometric mean (GM) potency ratios of B versus Wo/80 and geometric coefficients of variation (GCV)¹⁶ in the individual laboratories

Laboratory	Farr assay		Crithidia luciliae	
	GM	GCV(%)	GM	GCV(%)
1	0.37	18	0.30	94
2	0.29	7	0.50	0
3	0.26	13	0.39	39
4	0.31	3	0.25	0
5	0.35	9	0.35	49
6	0.31	12	0.40	49
7	0.32	9	0.50	0
8	—	—	0.25	0

—=not done.

ratios for the Farr assay lay between the two values (0.25 and 0.5) which were most commonly obtained in the *C luciliae* assay. The overall geometric mean potency ratios by the two methods were not significantly different, with the confidence interval for the mean potency ratio by the Farr assay being contained entirely within the confidence interval for the mean potency ratio by *C luciliae* assay.

The following conclusions were reached: (a) By the Farr assay the preparations Wo/80 and B gave parallel dilution curves as judged from graphical plots of percentage binding against log concentration; (b) Potency ratios of B v Wo/80 were significantly different among the individual laboratories for both assay methods, but the overall distributions were satisfactorily narrow. The geometric mean potency ratios by the two assay methods were not significantly different; (c) Preparation A was inactive by both methods in all laboratories.

Discussion

The purpose of the subcommittee on standardisation of anti-dsDNA was to make available a serum with antibodies to dsDNA which could serve as an international standard, enabling the expression of results of quantitative anti-dsDNA assays in international units. The WHO expert committee on biological standardisation agreed that the serum Wo/80 met these criteria and declared that each vial of 0.5 ml contains 100 international units of anti-dsDNA. The standard was designated: First international standard for anti-dsDNA.

In a recent study performed by 10 laboratories from all over the world, initiated by the Arthritis Foundation and Centers for Disease Control in Atlanta, it was shown that national standards could be calibrated in IU using Wo/80 as a reference preparation. All 10 laboratories considered Wo/80 to contain anti-dsDNA antibodies using various methods including enzyme linked immunosorbent assay (ELISA), the Farr assay, polyethylene glycol precipitation, Millipore filtration, complement fixation, and immunofluorescence techniques.

The vials are held and distributed by the International Laboratory for Biological Standards, located in the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, PO Box 9190, 1006 AD Amsterdam, The Netherlands. It is recommended that this standard is employed as a reference preparation for establishing national, regional, or local standards.

The patient was under care of Dr L Bouman of the Department of

International Medicine of the Free University of Amsterdam, and under regular observation by Dr A J G Swaak, who performed the study on the clinical significance of anti-DNA. Freeze drying and distribution of the vials was carried out by Mr G H Spiller, Amersham International plc. Tests for autoantibodies were performed under the supervision of Dr H G M Geertzen of the Department of Autoimmune Diseases of the Central Laboratory of the Blood Transfusion Service of Amsterdam. In the same department Dr R Smeenk performed the degradation tests. The following members of the subcommittee on standardisation of anti-dsDNA participated in the collaborative study: L A Aarden, G J Fournié, K Helmke, E J Holborow, G D Johnson, J Jonsson, R N Maini, A D Steinberg, E M Tan. Other members of the subcommittee were Dr Alarçon-Segovia, R M Bennett, R I Carr, A Fagraeus, I Hanna, J Holian, G R V Hughes, D Koffler, P Lambert, R W Lightfoot, P H Schur, D Stollar, N Talal. Amersham kits were kindly provided by Amersham International plc, and *Critidia luciliae* preparations by the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service.

References

- 1 Seligmann M. Serologie dans le serum des malades atteints de lupus erythematosus disseminé. *CR Acad Sci (Paris)* 1957; **249**: 243-55.
- 2 Ceppellini R, Polli E, Celada F. A DNA-reacting factor in the serum of a patient with lupus erythematosus diffus. *Proc Soc Exp Biol Med* 1957; **96**: 572-4.
- 3 Miesscher P, Strassle R. New serologic methods for the detection of the L.E. factor. *Vox Sang* 1957; **2**: 283-95.
- 4 Robbins W C, Holman H R, Deicher H R, Kunkel H J. Complement fixation with cell nuclei and DNA in lupus erythematosus. *Proc Soc Exp Biol Med* 1957; **96**: 575-9.
- 5 Feltkamp T E W, ed. The significance of the determination of anti-DNA and DNA/anti-DNA complexes. *Scand J Rheumatol* 1975; suppl 11.
- 6 Maini R N, Holborow E J, eds. Detection and measurement of anti-DNA antibodies. *Ann Rheum Dis* 1977; **36** (suppl 1).
- 7 Aarden L A, Smeenk R J T. Measurement of antibody specific for DNA. In: Lefkovits I, Pernis B, eds. *Immunologic methods*. Vol 2. New York: Academic Press, 1981: 75.
- 8 Smeenk R. A comparison of four different anti-DNA assays. In: Pal S B, ed. *Immunoassay technology*. Vol 2. Berlin: Walter de Gruyter, 1986: 145-66.
- 9 Aarden L A, Lakmaker F, De Groot E R. Immunology of DNA. IV. Quantitative aspects of the Farr assay. *J Immunol Methods* 1976; **11**: 153-63.
- 10 Aarden L A. Last minute subjects. *Scand J Rheumatol* 1977; (suppl 11): 65.
- 11 Kirkwood T B L. Predicting the stability of biological standards and products. *Biometrics* 1977; **33**: 736-42.
- 12 Kirkwood T B L, Tydeman M S. Design and analysis of accelerated degradation tests for the stability of biological standards. II. A flexible computer program for data analysis. *Biol Stand* 1984; **12**: 207.
- 13 Tydeman M S, Kirkwood T B L. Design and analysis of accelerated degradation tests for the stability of biological standards. I. Properties of maximum likelihood estimators. *Biol Stand* 1984; **12**: 195-206.
- 14 Holian J, Griffiths I D, Glass D N, Maini R N, Scott J. Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. *Ann Rheum Dis* 1975; **34**: 438-43.
- 15 Finney D J. *Statistical method in biological assay*. New York: Academic Press, 1978.
- 16 Kirkwood T B L. Geometric means and measures of dispersion. *Biometrics* 1979; **35**: 908.